TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Seeking Alpha
Michael Weiss, Chairman, CEO & President, stated that 2025 was a defining year for TG Therapeutics, emphasizing, "We delivered approximately $616 million in total global revenue, the vast majority of which came from $594 million of BRIUMVI U.S. net sales, and we Quick Insights Management reports strong sequential and year-over-year U.S. BRIUMVI net sales growth, citing durable patient retention, conservative full-year guidance, and growing repeat patient revenue, implying sustainable momentum. Management projects the subcutaneous BRIUMVI launch could nearly double the addressable market, though notes uncertainty on adoption pace and manageable incremental launch costs, while expecting expansion beyond current 35–40% subcu market share. The company completed a $100M buyback and authorized another $100M, expressing willingness to use leverage, believing shares are significantly undervalued, and affirming a more aggressive capital allocation stance. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 2/26/26 - Miss
TGTX
Sec Filings
- 2/27/26 - Form 10-K
- 2/26/26 - Form 8-K
- 1/29/26 - Form 4
- TGTX's page on the SEC website